Fresh news on bremelanotide:
'February 9, 2010
PALATIN TECHNOLOGIES, INC. ANNOUNCES DOSING OF SUBCUTANEOUS BREMELANOTIDE TRIAL IN MEN
CRANBURY, NJ – February 9, 2010 – Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Palatin anticipates completing the study in the current calendar quarter, with data analysis completed in the next calendar quarter.
“The current study is designed to validate our hypothesis that increases in blood pressure and gastrointestinal events seen with intranasally administered bremelanotide were primarily related to high intranasal absorption in a subset of patients. The results from this study in the male demographic we are targeting for commercialization, combined with results from our study reported last August, are intended to further address concerns raised by the Food and Drug Administration,” said Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin.
Data from this study will be submitted to the Food and Drug Administration. Palatin intends to initiate a Phase 2, at-home, study of subcutaneous bremelanotide in men with erectile dysfunction who are not responsive to therapies with drugs such as Viagra®, a brand of sildenafil citrate, in the second half of this calendar year. The Phase 2 bremelanotide erectile dysfunction program is designed to provide the data required to initiate Phase 3 registration trials.
“The commercial opportunity for bremelanotide is significant with an estimated market of $500 million to $600 million per year. About 35% of patients with erectile dysfunction do not respond to approved oral therapies, and with limited treatment options these patients are ideal candidates for subcutaneous bremelanotide,” stated Carl Spana, Ph.D., President and CEO of Palatin.'
Read more: Palatin Technologies - The Leader in Melanocortin-based Therapeutics
According to the press report I mentioned on my previous post, 2010 will be a good year for bremelanotide. Phase 2 trials are under way and we can expect some results soon.
I'm convinced that centrally acting drugs are the best solution for psychogenic ED. PDE-5 inhibitors and VIGAMED only work locally. Bremelanotide and ZORAXEL, by the contrary, go to the root of the problem (the brain) and may be even better.
Buffalobil, can you or anyone else suggest a source for Bremelanotide, Zoraxel, and Vigamed since you indicated you have tried some of these???
Sorry Curious, I have not been on the site for a while. If you are truly interested in giving it a go, I would recommend checking out Melantonin.org. It is not a highly active site but it has tons of great information and it is where i got started. This is after all unapproved and experiment and there are risks. You should familiarize yourself with the details before making the final decision. In addition to Bremelanotide many also use Melantonin II (not to be confused with Melatonin the sleep aid). It is a self tanning agent chemically similar to Bremelanotide. There is some anecdotal discussion that indicates it may be even a little more effective, but I haven't tried it yet. You should know that the delivery system is by subcutaneous injection (don't bother with the nasal spray). Some get freaked by that but it is a very tiny insulin needle and I cant even feel the damn thing. You have to mix it yourself and store it properly under refrigeration. It is a long period uptake (6 hours for me) and long lasting in effect. The actual effect it has is hard to quantify and I have written about it in more detail elsewhere in this forum if you should want to look it up. I also do some stacking primarily with vigamed.
If you decide to try it, I would recommend checking out http://www.tanresearch.com/ I have used him for years and never had a bad batch.
Good luck to you and if I can help in any way let me know.
Thanks for the PT141 use reports.
How long can you store the mixed PT141 batch in your refrigerator before it's no good?
Thats up for some debate. The conventional wisdom is 4 weeks although I have stories where it was stored for 3 months and it was still effective. The sight i mentioned sells a 2mg vial which is very nice. The other thing I do is pre-load the syringes, put them in the freezer and the take them out as i need them. I doesn't take long to slack out obviously. Hope it all helps
Thanks for the info bufallobil!
I am a recording engineer, and the news about the correlation between hearing loss and the PDE5 inhibitors has made me fairly unhappy of late. I suspect my wife is a little less happy as well.
Do you guys always use the entire 2mg of PT 141, or can you get by with less?
It's a tad on the expensive side.
It's kind of odd that you can by this with no legal issues; is there a catch of some sort? I had been following the developoement of Bremelanotide for a few years, but when the phase III trials neevr happened I assumed they had discovered a prohibitive side effect.
What's interesting to me is that there has been no huge outcry over the revelations concerning hearing loss and (the now standard) ED treatments. As far as I can tell there hasn't even been a ripple. I would predict that most men would probably be willing to sacrifice a few dB at 4 KHz for the ability to perform, and maybe this is why nothing much has been said about it.
It would be nice if it worked to the benefit of the up and coming treatment options though...
When my PT-141 arrives, I will need some appropriate needles; how best to obtain those? I checked melantonin.org, but it doesn't seem to exist!